SCHEMBL63644

SCHEMBL63644

CCOC(=O)c1nc(C2(NC(=O)OCc3ccccc3)CCC(OS(C)(=O)=O)CC2)[nH]c(=O)c1OS(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.37
ADORA3 P0DMS8 4/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
TLR2 O60603 2/20 0.33
CTSB P07858 2/20 0.33
CTSS P25774 2/20 0.33
CTSK P43235 2/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63988 0.86 ROCK2 (0.34) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL51513 0.86 ROCK2 (0.34) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL63358 0.81 RNASEH1 (0.43) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL51895 0.78 RNASEH1 (0.42) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL63522 0.77 RNASEH1 (0.41) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL52063 0.76 ROCK2 (0.34) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL52441 0.76 RNASEH1 (0.45) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL62555 0.75 RNASEH1 (0.43) ROCK2ADORA3NPC1RAB9AKMT2A
SCHEMBL63767 0.75 RNASEH1 (0.39) ROCK2ADORA3NPC1RAB9AADORA2A
SCHEMBL52517 0.75 RNASEH1 (0.39) ROCK2ADORA3NPC1RAB9AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ROCK2 1690/4885ADORA3 1885/4885NPC1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.